Email this article THE ROLE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER THE EMERGENCE OF MORE POWERFUL INHIBITORS OF P2Y12 RECEPTOR
- Authors: Gilyarevsky S.R.1, Larin A.G.1, Lopotovsky P.Y.1, Kuzmina I.M.1, Baturina O.V.1
-
Affiliations:
- Emergency Care Scientific-Research Institute named N.V. Sklifosovsky
- Issue: Vol 5, No 3 (2011)
- Pages: 95-102
- Section: PHARMACOTHERAPY
- Published: 17.07.2014
- URL: https://klinitsist.abvpress.ru/Klin/article/view/109
- DOI: https://doi.org/10.17650/1818-8338-2011-3-95-102
- ID: 109
Cite item
Full Text
Abstract
The role of P2Y12 receptor blocker clopidogrel after the introduction into clinical practice of new, more powerful and stable operating drugs belonging to this class of antiplatelet agents is discussed. The advantages and disadvantages of each of the currently used antiplatelet drugs that block the receptor P2Y12 are reviewed. On the basis of the analysis concludes that, despite the emergence of new antiplatelet agents clopidogrel, appears to be widely used for a long time in the treatment of patients with acute coronary syndrome and / or after coronary stenting. This is primarily due to the presence of large evidence base, and confirmation of safety of long-term therapy clopidogrel.
About the authors
S. R. Gilyarevsky
Emergency Care Scientific-Research Institute named N.V. Sklifosovsky
Author for correspondence.
Email: sgilarevsky@rambler.ru
Russian Federation
A. G. Larin
Emergency Care Scientific-Research Institute named N.V. SklifosovskyRussian Federation
P. Y. Lopotovsky
Emergency Care Scientific-Research Institute named N.V. SklifosovskyRussian Federation
I. M. Kuzmina
Emergency Care Scientific-Research Institute named N.V. SklifosovskyRussian Federation
O. V. Baturina
Emergency Care Scientific-Research Institute named N.V. SklifosovskyRussian Federation
References
Supplementary files
